I'll answer for Baxter, and maybe Stephen can answer for the industry.
My company doesn't make the kinds of products for those very unique, specialized patient populations, like ECMO, where the concern statements by Health Canada were focused. So again, it is in some very unique populations.
But I would say that already, where there are customers who have a specific request or need, or in cases like this where there has been a focus of attention, medical device manufacturers are providing what our customers are asking for. I would only reiterate that it is based on the functional performance and what the clinical application is.
As I understand the bill, there is a lack of science to indicate that there is a need for a general ban or even a general phase-out over time.